Polynovo Ltd

PNV: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|H@>$^W?LOCK|Q#LOCK|>G<&##C

Polynovo Earnings: Shares Undervalued on Solid Product Demand Despite Currency Headwinds

Polynovo's interim 2026 sales rose a solid 26% to AUD 68 million, driven by a 25% increase in US sales to AUD 52 million. Sales of its new alternative product that has no sealing membrane, Novosorb MTX, almost tripled to AUD 6 million. Underlying EBITDA grew 82% to AUD 5 million on cost control.

Sponsor Center